http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015517458-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| filingDate | 2013-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2015517458-A |
| titleOfInvention | Pharmaceutical composition |
| abstract | A combination comprising at least a first insulin-like compound and a second insulin-like compound for treating a condition or disease in a subject in need thereof where administration of insulin would be beneficial is described. The combination is an amount that achieves beneficial glycemic control in the subject as determined by the level of HbA 1c in the subject after administration of the combination at a maximum daily diet to the subject. The beneficial glycemic control by the combination is achieved by an equivalent dose of IGlar in the subject as determined by the level of HbA 1c in the subject after administration of IGlar to the subject HbA 1c level in the subject after administration of the combination at the maximum daily diet is superior to any glycemic control and / or the beneficial glycemic control by the combination is Reducing the first insulin-like compound to about 7 or less; wherein the first insulin-like compound comprises the second insulin-like compound The combination is administered on a daily maximum meal to the subject; the first insulin-like compound is at least a long-acting insulin, preferably a very long-acting form The first insulin-like compound is a naturally occurring derivative of insulin or an insulin analogue; the first insulin-like compound is the N-terminal amino acid residue of the B chain of the parent insulin And the side chain bonded to the ε-amino group of the Lys residue present in the B chain, wherein the side chain is represented by the general formula (I): —W—X—Y—Z Have. |
| priorityDate | 2012-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 237.